Atyr PHARMA (ATYR) Competitors

Ocular Therapeutix (NASDAQ:OCUL) and Atyr PHARMA (NASDAQ:ATYR) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their valuation, profitability, earnings, community ranking, media sentiment, risk, analyst recommendations, institutional ownership and dividends.

Which has better valuation and earnings, OCUL or ATYR?

Atyr PHARMA has lower revenue, but higher earnings than Ocular Therapeutix. Ocular Therapeutix is trading at a lower price-to-earnings ratio than Atyr PHARMA, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ocular Therapeutix	$63.72M	18.79	-$80.74M	-$1.26	-5.98
Atyr PHARMA	$235K	1,130.59	-$50.39M	-$0.87	-3.44

Is OCUL or ATYR more profitable?

Atyr PHARMA has a net margin of 0.00% compared to Ocular Therapeutix's net margin of -283.74%. Ocular Therapeutix's return on equity of -45.18% beat Atyr PHARMA's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ocular Therapeutix	-283.74%	-45.18%	-30.87%
Atyr PHARMA	N/A	-79.44%	-59.16%

Which has more risk and volatility, OCUL or ATYR?

Ocular Therapeutix has a beta of 1.49, indicating that its stock price is 49% more volatile than the S&P 500. Comparatively, Atyr PHARMA has a beta of 0.95, indicating that its stock price is 5% less volatile than the S&P 500.

Does the MarketBeat Community favor OCUL or ATYR?

Ocular Therapeutix received 429 more outperform votes than Atyr PHARMA when rated by MarketBeat users. However, 100.00% of users gave Atyr PHARMA an outperform vote while only 70.27% of users gave Ocular Therapeutix an outperform vote.

Company	Underperform	Outperform
Ocular Therapeutix	Outperform Votes 442 70.27%	Underperform Votes 187 29.73%
Atyr PHARMA	Outperform Votes 13 100.00%	Underperform Votes No Votes

Do insiders and institutionals hold more shares of OCUL or ATYR?

59.2% of Ocular Therapeutix shares are owned by institutional investors. Comparatively, 61.7% of Atyr PHARMA shares are owned by institutional investors. 3.5% of Ocular Therapeutix shares are owned by insiders. Comparatively, 3.7% of Atyr PHARMA shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Do analysts recommend OCUL or ATYR?

Ocular Therapeutix currently has a consensus target price of $16.38, indicating a potential upside of 117.46%. Atyr PHARMA has a consensus target price of $18.60, indicating a potential upside of 522.07%. Given Atyr PHARMA's stronger consensus rating and higher possible upside, analysts clearly believe Atyr PHARMA is more favorable than Ocular Therapeutix.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ocular Therapeutix	0 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.89
Atyr PHARMA	0 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	3.14

Does the media favor OCUL or ATYR?

In the previous week, Ocular Therapeutix had 8 more articles in the media than Atyr PHARMA. MarketBeat recorded 13 mentions for Ocular Therapeutix and 5 mentions for Atyr PHARMA. Atyr PHARMA's average media sentiment score of 1.37 beat Ocular Therapeutix's score of 0.66 indicating that Atyr PHARMA is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Ocular Therapeutix	2 Very Positive mention(s)	1 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Atyr PHARMA	3 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Atyr PHARMA beats Ocular Therapeutix on 12 of the 19 factors compared between the two stocks.